Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats

[1]  J. Ma,et al.  Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation. , 2011, Journal of medicinal food.

[2]  J. Barkin.  Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. , 2011, The Canadian journal of urology.

[3]  Ho Young Lee,et al.  Evaluation of genotoxicity of Yukmijihwang-tang, a herbal formula. , 2011, Regulatory toxicology and pharmacology : RTP.

[4]  A. Vikram,et al.  Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth , 2011, Steroids.

[5]  A. Traish,et al.  Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. , 2011, The journal of sexual medicine.

[6]  Ho Young Lee,et al.  Safety Evaluation of Yukmijihwang-tang: Assessment of Acute and Subchronic Toxicity in Rats , 2010, Evidence-based complementary and alternative medicine : eCAM.

[7]  C. Roehrborn.  Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). , 2011, The Medical clinics of North America.

[8]  U. Ha,et al.  Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. , 2010, Journal of agricultural and food chemistry.

[9]  W. Lee,et al.  Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1alpha. , 2010, The Journal of nutritional biochemistry.

[10]  P. Pais,et al.  Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5α-reductase II , 2010, Advances in therapy.

[11]  Saurabh Aggarwal,et al.  An overview on 5α-reductase inhibitors , 2010, Steroids.

[12]  Anup A. Patil,et al.  Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. , 2010, European journal of pharmacology.

[13]  M. Oelke,et al.  Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH , 2009, World Journal of Urology.

[14]  E. Keller,et al.  Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. , 2009, Endocrine-related cancer.

[15]  T. Tarter,et al.  Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate , 2009, Clinical interventions in aging.

[16]  R. Rittmaster,et al.  Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. , 2008, Urology.

[17]  C. Roehrborn,et al.  Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily , 2008, Clinical interventions in aging.

[18]  W. Zhong,et al.  Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. , 2008, Clinical and investigative medicine. Medecine clinique et experimentale.

[19]  M. Messaoudi,et al.  Preventive effects of ACTICOA powder, a cocoa polyphenolic extract, on experimentally induced prostate hyperplasia in Wistar-Unilever rats. , 2007, Journal of medicinal food.

[20]  M. Oh,et al.  Yukmijihwang-tang protects against cyclophosphamide-induced reproductive toxicity. , 2007, Reproductive toxicology.

[21]  K. McVary.  A review of combination therapy in patients with benign prostatic hyperplasia. , 2007, Clinical therapeutics.

[22]  M. Messaoudi,et al.  Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract, on experimentally induced prostate hyperplasia in Wistar-Unilever rats. , 2007, Journal of medicinal food.

[23]  H. Bae,et al.  Effects of Yukmijihwang-tang derivatives (YMJd) on ibotenic acid-induced amnesia in the rat. , 2008, Biological and Pharmaceutical Bulletin.

[24]  Y. Mun,et al.  Yukmijihwang-tang ameliorates ischemia/reperfusion-induced renal injury in rats. , 2006, Journal of ethnopharmacology.

[25]  M. Naslund,et al.  An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. , 2006, The American journal of managed care.

[26]  V. Ed,et al.  Inhibitors of 5α-reductase in the treatment of benign prostatic hyperplasia , 2006 .

[27]  T. Bullock,et al.  Emerging drug therapies for benign prostatic hyperplasia , 2006, Expert opinion on emerging drugs.

[28]  R. Más,et al.  Effect of D-004, a Lipid Extract from the Cuban Royal Palm Fruit, on Atypical Prostate Hyperplasia Induced by Phenylephrine in Rats , 2006, Drugs in R&D.

[29]  E. Vaughan,et al.  Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. , 2006, Current pharmaceutical design.

[30]  W. V. van Cappellen,et al.  Nuclear Dynamics of PCNA in DNA Replication and Repair , 2005, Molecular and Cellular Biology.

[31]  Xiao-yan Qi,et al.  [Effect of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients]. , 2004, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[32]  D. Tindall,et al.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. , 2004, The Journal of urology.

[33]  Culley Carson,et al.  The role of dihydrotestosterone in benign prostatic hyperplasia. , 2003, Urology.

[34]  Ming-Ling Kuo,et al.  The effect of liu-wei-di-huang wan on cytokine gene expression from human peripheral blood lymphocytes. , 2003, The American journal of Chinese medicine.

[35]  H. Huynh.  Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. , 2002, International journal of oncology.